Lake Street raised the firm’s price target on Aquestive Therapeutics to $8 from $3 and keeps a Buy rating on the shares. Management has found “creative, effective solutions to circumvent the challenging capital markets that have plagued the biotech community” and the stage is “set for an eventful 2024” with Libervant’s potential April FDA approval and Anaphylm’s anticipated NDA submission by year-end, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AQST:
- Aquestive Therapeutics Updates Investors with Presentation and Financials
- Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Aquestive Therapeutics options imply 25.7% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 05, 2024
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
